A Randomized, Controlled, Crossover Trial of Fish Oil Treatment for Impulsive Aggression in Children and Adolescents with Disruptive Behavior Disorders

2014 ◽  
Vol 24 (3) ◽  
pp. 140-148 ◽  
Author(s):  
Angela J. Dean ◽  
William Bor ◽  
Kareen Adam ◽  
Francis G. Bowling ◽  
Mark A. Bellgrove
Keyword(s):  
Fish Oil ◽  
Children And Adolescents ◽  
Disruptive Behavior ◽  
Behavior Disorders ◽  
Crossover Trial ◽  
Disruptive Behavior Disorders ◽  
Randomized Controlled ◽  
Impulsive Aggression

Neurobiological, Neuroimaging, and Neuropsychological Studies of Children and Adolescents with Disruptive Behavior Disorders

2016 ◽  
Vol 65 (1) ◽  
pp. 134-150 ◽  
Author(s):  
Ignazio Puzzo ◽  
Areti Smaragdi ◽  
Karen Gonzalez ◽  
Nayra Martin-Key ◽  
Graeme Fairchild
Keyword(s):  
Children And Adolescents ◽  
Disruptive Behavior ◽  
Behavior Disorders ◽  
Disruptive Behavior Disorders

Neuroendocrine responses to challenge with dl-fenfluramine and aggression in disruptive behavior disorders of children and adolescents

1992 ◽  
Vol 43 (3) ◽  
pp. 263-276 ◽  
Author(s):  
David M. Stoff ◽  
Abner P. Pasatiempo ◽  
Jupiter Yeung ◽  
Thomas B. Cooper ◽  
Wagner H. Bridger ◽  
...  
Keyword(s):  
Children And Adolescents ◽  
Disruptive Behavior ◽  
Behavior Disorders ◽  
Disruptive Behavior Disorders ◽  
Neuroendocrine Responses

Pharmacological Treatments for Attention-Deficit/Hyperactivity Disorder and Disruptive Behavior Disorders

2015 ◽  
Author(s):  
Erica Kass ◽  
Jonathan E. Posner ◽  
Laurence L. Greenhill
Keyword(s):  
Attention Deficit Hyperactivity Disorder ◽  
Randomized Controlled Trials ◽  
Disruptive Behavior ◽  
Attention Deficit ◽  
Behavior Disorders ◽  
Disruptive Behavior Disorders ◽  
Controlled Trials ◽  
Type I ◽  
Hyperactivity Disorder ◽  
Randomized Controlled

More than 225 placebo-controlled type 1 investigations demonstrate that psychostimulants are highly effective in reducing core symptoms of attention-deficit/hyperactivity disorder (ADHD) in children and adults. In contrast, there are limited type I studies demonstrating that psychopharmacological management with U.S. Food & Drug Administration-approved agents for ADHD (stimulants and nonstimulants), atypical antipsychotics, and mood stabilizers decrease the defiant and aggressive behavior characteristic of disruptive behavior disorders. Stimulant treatment evidence has been supplemented by two large multisite randomized controlled trials. Randomized controlled trials from the past 15 years continue to report several key adverse events associated with stimulants but have not supported rarer and more serious problems. Although psychostimulants have been shown to retain their efficacy for as long as 14 months, their long-term academic and social benefits are not as robust. Nonstimulant agents for which there is more limited evidence of efficacy include atomoxetine, alpha-agonists, modafinil, and bupropion.

scholarly journals Randomized Controlled Trial of Exercise for ADHD and Disruptive Behavior Disorders

2016 ◽  
Vol 48 (7) ◽  
pp. 1397-1407 ◽  
Author(s):  
EDUARDO ESTEBAN BUSTAMANTE ◽  
CATHERINE LUCY DAVIS ◽  
STACY LYNN FRAZIER ◽  
DANA RUSCH ◽  
LOUIS F. FOGG ◽  
...  
Keyword(s):  
Randomized Controlled Trial ◽  
Disruptive Behavior ◽  
Behavior Disorders ◽  
Controlled Trial ◽  
Disruptive Behavior Disorders ◽  
Randomized Controlled
Sign in / Sign up

Export Citation Format

Share Document